Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia (Q33747668)

29 July 2017

Augmented and standard Berlin-Frankfurt-Munster chemotherapy for treatment of adult acute lymphoblastic leukemia (English)

1 reference

29 July 2017

1 reference

1 reference

lymphoblastic leukemia

1 reference

6

Jack Lionberger

1 reference

29 July 2017

Julie E Chang

1

1 reference

29 July 2017

Stephen C Medlin

2

1 reference

29 July 2017

Brad S Kahl

3

1 reference

29 July 2017

Walter L Longo

4

1 reference

29 July 2017

Eliot C Williams

5

1 reference

29 July 2017

Kyungmann Kim

7

1 reference

29 July 2017

Jihoon Kim

8

1 reference

29 July 2017

Elizabeth Esterberg

9

1 reference

29 July 2017

Mark B Juckett

10

1 reference

29 July 2017

1 December 2008

1 reference

29 July 2017

1 reference

29 July 2017

49

1 reference

29 July 2017

12

1 reference

29 July 2017

2298-2307

1 reference

What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies

29 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

The changing scene of adult acute lymphoblastic leukemia

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

Clinical characteristics, biologic features and outcome for young adult patients with acute lymphoblastic leukaemia

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL).

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

Augmented Berlin-Frankfurt-Munster therapy abrogates the adverse prognostic significance of slow early response to induction chemotherapy for children and adolescents with acute lymphoblastic leukemia and unfavorable presenting features: a report fr

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

Treatment of adult acute lymphoblastic leukemia.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

The biology and treatment of acute lymphoblastic leukemia in adults.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

Intensified therapy in acute lymphoblastic and acute undifferentiated leukemia in adults.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

Evaluation of survival data and two new rank order statistics arising in its consideration

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969.

14 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

Intensive therapy for children with acute lymphoblastic leukaemia and unfavourable presenting features. Early conclusions of study CCG-106 by the Childrens Cancer Study Group.

14 July 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802517732

Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802517732

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802517732

Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802517732

Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802517732

Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802517732

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolid

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190802517732

A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2844086

Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia

30 October 2018

1 reference

12 December 2020

Should adolescents with acute lymphoblastic leukemia be treated as old children or young adults? Comparison of the French FRALLE-93 and LALA-94 trials

1 reference

12 December 2020

Acute lymphoblastic leukemia

1 reference

12 December 2020

Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial

1 reference

12 December 2020

[The BFM 76/79 acute lymphoblastic leukemia therapy study (author's transl)]

1 reference

12 December 2020

Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols

1 reference

12 December 2020

Treatment of acute lymphoblastic leukemia in adults with intensive induction, consolidation, and maintenance chemotherapy

1 reference

12 December 2020

Acute lymphoblastic leukemia in patients aged 60 years and over: a population-based study of incidence and outcome

1 reference

12 December 2020

The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties

1 reference

12 December 2020

Augmented post-induction therapy for children with high-risk acute lymphoblastic leukemia and a slow response to initial therapy

1 reference

12 December 2020

Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands

1 reference

12 December 2020

10.1080/10428190802517732

Identifiers

DOI

1 reference

29 July 2017

1 reference

29 July 2017

1 reference